- Home
- ALXO vs CLRB Comparison
ALXO vs CLRB Comparison
Compare ALXO & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- CLRB
- Stock Information
- Founded
- ALXO 2015
- CLRB 2002
- Country
- ALXO United States
- CLRB United States
- Employees
- ALXO N/A
- CLRB N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- ALXO Health Care
- CLRB Health Care
- Exchange
- ALXO Nasdaq
- CLRB Nasdaq
- Market Cap
- ALXO 81.1M
- CLRB 76.0M
- IPO Year
- ALXO 2020
- CLRB N/A
- Fundamental
- Price
- ALXO $1.41
- CLRB $1.58
- Analyst Decision
- ALXO Strong Buy
- CLRB Strong Buy
- Analyst Count
- ALXO 6
- CLRB 2
- Target Price
- ALXO $14.20
- CLRB $20.00
- AVG Volume (30 Days)
- ALXO 886.3K
- CLRB 517.5K
- Earning Date
- ALXO 11-07-2024
- CLRB 11-18-2024
- Dividend Yield
- ALXO N/A
- CLRB N/A
- EPS Growth
- ALXO N/A
- CLRB N/A
- EPS
- ALXO N/A
- CLRB N/A
- Revenue
- ALXO N/A
- CLRB N/A
- Revenue This Year
- ALXO N/A
- CLRB N/A
- Revenue Next Year
- ALXO N/A
- CLRB N/A
- P/E Ratio
- ALXO N/A
- CLRB N/A
- Revenue Growth
- ALXO N/A
- CLRB N/A
- 52 Week Low
- ALXO $1.19
- CLRB $1.39
- 52 Week High
- ALXO $17.83
- CLRB $4.45
- Technical
- Relative Strength Index (RSI)
- ALXO 47.30
- CLRB 21.39
- Support Level
- ALXO $1.19
- CLRB $1.39
- Resistance Level
- ALXO $1.63
- CLRB $2.18
- Average True Range (ATR)
- ALXO 0.11
- CLRB 0.14
- MACD
- ALXO 0.01
- CLRB -0.06
- Stochastic Oscillator
- ALXO 50.00
- CLRB 23.46
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.